44 participants
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2023-11-18
- Start Date:
- 2019-03-05
- Completion:
- 2022-05-04
Conditions
- Refractory Solid Tumors
Interventions
- DRUG
No Results Yet